Personalis (PSNL) Company Report

On November 7, 2025, Personalis, Inc.'s ultrasensitive NeXT Personal® test received Medicare coverage.
This coverage, effective retroactively as of October 7, 2025, is for post-treatment surveillance of cancer recurrence in patients with stage II and III breast cancer.
The Centers for Medicare & Medicaid Services Molecular Diagnostics Program determined reimbursement rates of $3,878 for the NeXT Personal Dx Breast MRD Recurrence Monitoring Test and $1,158 for the NeXT Personal Single Plasma Test.

Nov 10, 2025, 2:11 PM

8-K

Personalis Announces Medicare Coverage for NeXT Personal Test

PSNL

Product Launch

New Projects/Investments

Personalis, Inc. announced Medicare coverage for its ultrasensitive NeXT Personal® test for surveillance of cancer recurrence in breast cancer patients.
The coverage applies to Medicare beneficiaries with stage II and III breast cancer, including all three major subtypes, for up to six years in the surveillance setting.
A study published this year indicated the NeXT Personal test detected 100% of breast cancer recurrences a median of ~15 months, and up to ~5 years, ahead of standard-of-care radiographic imaging.

Nov 10, 2025, 2:00 PM

Press Release

Personalis Announces Q3 2025 Results and Updates Full-Year Guidance

PSNL

Earnings

Guidance Update

Demand Weakening

Personalis (PSNL) reported Q3 2025 revenue of $14.5 million, representing a 44% decrease compared to the prior year, primarily driven by expected declines from Natera and VA MVP, and a 16% decrease in biopharma revenue.
The company delivered 4,388 clinical tests for NeXT Personal in Q3 2025, achieving 26% sequential growth and 364% year-over-year growth, with over 700 physicians now ordering the test.
Full-year 2025 revenue guidance was adjusted to a range of $68-$73 million from the previous $70-$80 million, attributed to logistical delays and variability in biopharma project timing.
Personalis ended Q3 2025 with $150.5 million in cash and short-term investments and maintained its full-year 2025 cash usage estimate of approximately $75 million.
The company has three dossiers under review with MolDX for coverage, including a recent submission for lung cancer, and continues to target two coverage decisions in 2025.

Nov 4, 2025, 10:00 PM

Transcript

Personalis, Inc. Reports Third Quarter 2025 Financial Results and Updates Full-Year Guidance

PSNL

Earnings

Guidance Update

Demand Weakening

Personalis, Inc. reported Q3 2025 revenue of $14.5 million, a 44% decrease compared to $25.7 million in Q3 2024, resulting in a net loss of $21.7 million ($0.24 per share).
Despite the overall revenue decline, the company achieved 364% year-over-year growth in clinical test volume, delivering 4,388 clinical tests in Q3 2025, driven by increasing physician adoption of the NeXT Personal platform.
Personalis updated its full-year 2025 total company revenue guidance to a range of $68.0 to $73.0 million, a reduction from the prior guidance of $70.0 to $80.0 million, while maintaining its net loss guidance at approximately $85 million.
The company submitted a third dossier for Medicare coverage and presented positive new lung cancer data from AstraZeneca's Phase 3 NeoADAURA and LAURA trials, advancing its "Win-in-MRD" strategy.

Nov 4, 2025, 9:09 PM

8-K

Personalis Reports Q3 2025 Financial Results and Updates Full-Year Guidance

PSNL

Earnings

Guidance Update

Demand Weakening

Personalis reported revenue of $14.5 million for the third quarter of 2025, a 44% decrease compared to $25.7 million in Q3 2024, and a net loss of $21.7 million, or $0.24 per share.
Despite the revenue decline, the company delivered 4,388 clinical tests in Q3 2025, marking a 364% year-over-year growth and a 26% sequential increase over Q2 2025, driven by increasing physician adoption of the NeXT Personal platform.
Personalis submitted a third dossier for Medicare coverage for lung cancer and presented positive clinical data from the AstraZeneca NeoADAURA and LAURA trials, supporting its "Win-in-MRD" strategy.
For the full year 2025, Personalis updated its total company revenue guidance to a range of $68.0 to $73.0 million (reduced from prior guidance of $70.0 to $80.0 million) and maintained its net loss outlook at approximately $85 million.

Nov 4, 2025, 9:01 PM

Press Release

Personalis Announces New Data from Lung Cancer Trial

PSNL

New Projects/Investments

Product Launch

Personalis announced new data from AstraZeneca's phase 3 LAURA clinical trial, highlighting its NeXT Personal® molecular residual disease (MRD) test as a useful tool for assessing maintenance treatment response in EGFR-mutated non-small cell lung cancer.
The LAURA analysis demonstrated that NeXT Personal enabled MRD clearance tracking post-chemoradiotherapy and detected MRD progression with a median lead time of 5 months ahead of standard disease progression assessment.
This data reinforces NeXT Personal's capabilities, building on prior studies where it detected cancer DNA up to ~16 months ahead of standard imaging in cervical cancer.

Oct 16, 2025, 1:00 PM

Press Release

Personalis Reports Positive Phase 3 Trial Data for NeXT Personal Test

PSNL

New Projects/Investments

Product Launch

Personalis announced new data from a Phase 3 AstraZeneca clinical trial (NeoADAURA) demonstrating its NeXT Personal® molecular residual disease (MRD) test is a strong predictor of outcomes in patients with lung cancer.
The NeXT Personal test showed significantly higher baseline sensitivity for ctDNA detection, was a strong prognosticator of clinical outcomes, and proved useful for monitoring neoadjuvant therapy response in the trial.
These findings support the utility of NeXT Personal in helping doctors understand patient response to neoadjuvant therapy and guiding future treatment decisions.
Personalis has recently submitted for Medicare coverage for its NeXT Personal liquid biopsy test for use in lung cancer, marking the third indication for which the company is seeking coverage.

Sep 3, 2025, 8:05 PM

Press Release

Personalis Reports Second Quarter 2025 Financial Results and Updates Full-Year Guidance

PSNL

Earnings

Guidance Update

Personalis reported Q2 2025 revenue of $17.2 million, a 24% decrease compared to Q2 2024, and a net loss of $20.1 million.
The company delivered 3,478 clinical tests in Q2 2025, representing a 59% sequential increase over Q1 2025, demonstrating accelerating physician adoption of the NeXT Personal® platform.
Personalis updated its full-year 2025 guidance, reducing total company revenue expectations to a range of $70 to $80 million (from $80 to $90 million) and increasing the projected net loss to approximately $85 million (from $83 million).

Aug 5, 2025, 8:01 PM

Press Release

Personalis Expands Collaboration with Tempus AI

PSNL

New Projects/Investments

Product Launch

Personalis has expanded its strategic collaboration with Tempus AI, Inc. to include colorectal cancer (CRC) as a new indication for its NeXT Personal® ultra-sensitive, tumor-informed minimal residual disease (MRD) test.
This expansion means the NeXT Personal test will now cover four major cancer types: breast, lung, and colorectal cancers, and solid tumor immunotherapy monitoring.
The agreement's term has been extended to November 2029, and Tempus's exclusivity for all four indications is lengthened through 2028.
The addition of CRC follows compelling interim analysis results from the VICTORI study, and colorectal cancer affects over 150,000 new patients in the U.S. annually.

Jul 9, 2025, 8:00 PM

Press Release

Earnings Transcripts

Quarterly earnings call transcripts for Personalis.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Christopher Hall say about margins?What are Personalis's strategic priorities?How is Personalis positioned vs competitors?How did Personalis do last quarter?

Let Fintool AI Agent track Personalis's earnings for you

Get instant analysis when filings drop